Enhanced sensitization to paclitaxel-induced apoptotic effect on breast cancer cells SKBr3 by engineered antibody treatment
- VernacularTitle:基因工程抗体增强紫杉醇诱导乳腺癌细胞SKBr3凋亡的作用
- Author:
Huijing YIN
;
Liansheng CHENG
- Publication Type:Journal Article
- Keywords:
Anti-p185c-erbB-2/neu engineered antibody;
Paclitaxel;
Apoptosis;
AKt/NF-?B pathway;
Maligant breast cancer
- From:
Chinese Journal of Immunology
1985;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the enhanced sensitization to chemotherapeutic agent paclitaxel-induced apoptotic effect on p185-overexpressing human malignant breast cancer cell lines SKBr3 by anti-p185c-erbB-2/neu engineered antibody treatment and to study its emerging mechanism.Methods:The proliferative inhibitory effect was assessed by MTS assay; Cells stained with AnnexinV-FITC and PI were used to qualify the apoptotic cell number by FACS(Fluorescence-activated cell sorting) analysis; Phosphorylation of Ser473 AKt and p65 NF-?B subunit were determined by Western blot; NF-?B-DNA binding activity was demonstrated by EMSA(Electrophoretic mobility shift assay).Results:Anti-p185c-erbB-2/neu engineered antibody rendered SKBr3 cells more susceptible to paclitaxel-induced proliferative inhibition, which further attributed to apoptotic induction; Furthermore, combination of the engineered antibody and paclitaxel also showed effective suppression of AKt/NF-?B pathway in SKBr3 cells.Conclusion:The aggressiveness of AKt/NF-?B pathway was partly attributed to its resistance to paclitaxel-induced apoptosis. Anti-p185c-erbB-2/neu engineered antibody plus paclitaxel combination rendered p185-overexpressing human malignant breast cancer cells SKBr3 more susceptible to paclitaxel-induced apoptosis by efficient suppression of AKt/NF-?B pathway.
